JAMA
Nicotinamide riboside did not improve early Parkinson disease
In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.In a 52-week randomised trial, disease rating scores rose by 2.45 points with the supplement compared with a 0.27-point fall with placebo.
Randomised trial in 393 peopleNicotinamide riboside